Ensuring new medicines reach those in most need

Essential medicines for universal health coverage

“…Generic companies with MPP licences have supplied more than 7 million patient-years of WHO-recommended antiretroviral drugs in 117 countries, including 41 countries that were previously unable to benefi t from generic competition for such medicines • MPP licences enable manufacturing and sale of generic adult antiretroviral medicines to 87-93% of people with HIV in the developing world, which includes all 34 low-income countries and 55-80% of middle-income countries • MPP sublicensees supplied 4·3 million patient-years of tenofovir disoproxil fumarate in the fi rst 6 months of 2012, shortly after the agreement was reached The total direct global savings generated by the MPP406 are estimated at $2·2 billion by 2028, implying that for every dollar spent, the global community gains $40407 …”